Amneal Pharmaceuticals(US:AMRX) Zacks Investment Researchยท2024-03-01 13:16Company Performance - Amneal Pharmaceuticals reported quarterly earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.07 per share, but down from $0.23 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $616.98 million for the quarter ended December 2023, missing the Zacks Consensus Estimate by 2.17%, compared to $609.76 million in the same quarter last year [1] - Over the last four quarters, Amneal has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [1] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $604.52 million, and for the current fiscal year, it is $0.58 on revenues of $2.58 billion [4] - The estimate revisions trend for Amneal is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [4] Industry Context - The Medical - Drugs industry, to which Amneal belongs, is currently in the top 39% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [5] - Marinus Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.64 per share, reflecting a year-over-year change of +15.8%, with revenues anticipated to be $7.78 million, up 8.7% from the previous year [5][6]